MAZE vs VIR: stock comparison and AI forecast
Maze Therapeutics, Inc. (MAZE) and Vir Biotechnology, Inc. (VIR) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
MAZE Maze Therapeutics, Inc.
- Price
- $32.25 +21.4% · 6M
- Market Cap
- $1.79B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
VIR Vir Biotechnology, Inc.
- Price
- $11.75 +15.0% · 6M
- Market Cap
- $1.99B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- VIR is 1.1 times larger than MAZE by market capitalization ($1.99B against $1.79B).
- Over the last six months MAZE returned +21.4% and VIR +15.0%.
- VIR turns -68.5% of its revenue into net income, against -334.0% for MAZE.
- VIR carries 0.24 times debt per unit of equity, against 0.17 times for MAZE.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | MAZE | VIR |
|---|---|---|
| Market Cap | $1.79B | $1.99B |
| P/B Ratio | 3.95x | 2.02x |
| EPS | $-1.89 | $-1.89 |
| Book Value/Share | $8.16 | $5.81 |
| FCF/Share | $-1.92 | $-1.20 |
Profitability & Margins
| Metric | MAZE | VIR |
|---|---|---|
| ROE | -29.5% | -25.6% |
| ROA | -25.1% | -20.7% |
| ROIC | -28.6% | -25.0% |
| Gross Margin | – | 83.7% |
| Operating Margin | -364.0% | -76.3% |
| Net Margin | -334.0% | -68.5% |
| EBT Margin | -281.7% | -68.4% |
| Tax Rate | – | -0.1% |
Financial Health
| Metric | MAZE | VIR |
|---|---|---|
| Current Ratio | 18.31x | 6.04x |
| D/E Ratio | 0.17x | 0.24x |
| Financial Leverage | 1.17x | 1.24x |
| Working Capital | $397M | $479M |
Cash Flow
| Metric | MAZE | VIR |
|---|---|---|
| Operating Cash Flow | -$107M | -$203M |
| Free Cash Flow | -$107M | -$204M |
| Capital Spending | -$300K | -$1M |
Operational Efficiency
| Metric | MAZE | VIR |
|---|---|---|
| Payables Period | – | 249239 days |
Income Statement
| Metric | MAZE | VIR |
|---|---|---|
| Operating Income | -$146M | -$280M |
| Net Income | -$134M | -$252M |
| R&D Expense | $122M | $484M |
| SG&A Expense | – | $99M |
| Cost of Goods Sold | – | $30K |
Dividend & Shareholder Information
| Metric | MAZE | VIR |
|---|---|---|
| Shares Outstanding | 56M | 169M |
MAZE vs VIR: stock comparison and AI forecast
Which is bigger, MAZE or VIR?
VIR is 1.1 times larger than MAZE by market capitalization ($1.99B against $1.79B).
Which stock performed better over the last six months, MAZE or VIR?
Over the last six months MAZE returned +21.4% and VIR +15.0%.
Which one does Intratio's AI model rank higher, MAZE or VIR?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.